Bajaj Healthcare Ltd hits fresh 52-week high on launch of Ivermectin tablets for Covid-19

Our Bureau Mumbai | Updated on May 06, 2021

The drug will be available as a prescription-based medication

The shares of Bajaj Healthcare Ltd recorded a fresh 52-week high after the company launched Ivermectin tablets for the treatment of Covid-19.

At 12:45 pm, Bajaj Healthcare was trading at ₹624.05 on the BSE, up ₹36.65 or 6.24 per cent. It touched a 52-week high of ₹625.00. It had opened at ₹586.90 as against the previous close of ₹587.40.

The company on Thursday announced the launch of “Ivejaj” (Ivermectin) an AntiParasitic Drug now widely used in control & treatment for Covid-19 patients.

Also read: Bajaj Group commits ₹200 crore to fight Covid-19

“BHL has received approval from India's drug regulator, to manufacture and market “Ivejaj” the oral Ivermectin approved medication in India for the treatment of Covid-19 from 6th May 2021,” it said in a regulatory filing.

It has successfully developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team, it said.

The drug will be available as a prescription-based medication, with recommended doses.

Published on May 06, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor